News
The latest DDF and portfolio news.
Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550
– SUDO-550 is a potential best-in-class, orally administered, brain-penetrant TYK2 inhibitor being developed for the treatment of neuroinflammatory diseases. – (…)
Nitrase Therapeutics Presents Preclinical Data Demonstrating Antibody Prevents Spread of Pathology of Parkinson’s Disease at SfN’s Neuroscience 2024 Scientific Congress
-Development Candidate NDC-0524 is a First-in-Class, Humanized Therapeutic Antibody with High Affinity and Selectivity for Nitrated -Synuclein, which is Rapidly Being (…)
LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors’ Dementia Discovery (…)
QurAlis Doses First Participant Cohort in Phase 1 Multiple-Ascending Dose (MAD) Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
QRL-101 aims to reduce hyperexcitability-induced neurodegeneration, which is present in approximately 50 percent of all ALS patients Completed Phase 1 (…)
Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fund and Two Bear Capital to Develop Safer, More Effective Neuroscience Drugs Using a Novel Brain-Only Pharmacology Approach
Many neurological therapies exhibit dose-limiting side effects, and numerous neurological disease targets remain undruggable because of on-target off-tissue peripheral side (…)
Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001
Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme (…)
Cumulus Neuroscience Announces First Patient Enrolled in AccelADx Electroencephalogram (EEG) Study for Early Detection of Alzheimer’s Dementia
NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer’s Dementia. Cumulus Neuroscience today announced the enrollment (…)
Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference
-Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic (…)
Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia
TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP (…)
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader Deep degradation of (…)
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesis Refined focus (…)
Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for theTreatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases
24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a keybiomarker of neurodegeneration in tauopathies (…)
AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
• AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain (…)
Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
Boston, MA – August 28, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision (…)
Violet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV)
Round led by the DDF (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and founding investor (…)
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Therini Bio, Inc., a biotech company focused on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and (…)
Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting
BRISBANE, Calif., April 18, 2023 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build (…)
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
First patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a therapy that (…)
ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA (…)
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round Financing supports clinical activities for Company’s two lead programs (…)
Cerevance Expands Series B Financing with Additional $51 Million
Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase (…)
QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration CAMBRIDGE, Mass., January 5, 2023 – QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision (…)
QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
First ever study to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients expected to initiate in Canada in (…)
Nitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium
Company discovered selective nitration and regulation of tumor-intrinsic and immuno-oncology targets by several of its proprietary nitrases BRISBANE, Calif., Oct. (…)
Nitrase Therapeutics Appoints Arun Kashyap, Ph.D., to Lead its Recently Launched Oncology Programs as Senior Vice President of Oncology
BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build (…)
Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics
–Founder Irene Griswold-Prenner, Ph.D., Focuses on Role as Chief Scientific Officer—San Francisco, CA – November 2, 2021 – Nitrase Therapeutics, Inc. (…)
Why Bill Gates is optimistic about the future of Alzheimer’s research
By loading the video, you agree to YouTube’s privacy policy.Learn more Load video Always unblock YouTube PGlmcmFtZSBsb2FkaW5nPSJsYXp5IiB3aWR0aD0iMTAwJSIgaGVpZ2h0PSI0ODAiIHNyYz0iaHR0cHM6Ly93d3cueW91dHViZS1ub2Nvb2tpZS5jb20vZW1iZWQvTi14WWhGb3FjeUkiIGZyYW1lYm9yZGVyPSIwIiBhbGxvdz0iYWNjZWxlcm9tZXRlcjsgYXV0b3BsYXk7IGVuY3J5cHRlZC1tZWRpYTsgZ3lyb3Njb3BlOyBwaWN0dXJlLWluLXBpY3R1cmUiIGFsbG93ZnVsbHNjcmVlbj0iIj48L2lmcmFtZT4= If we want (…)
GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, (…)
The Dementia Discovery Fund’s Portfolio Company Caraway Therapeutics Establishes Collaboration with AbbVie to develop small molecule therapeutics targeting Parkinson’s disease and other neurodegenerative disorders
Boston, MA (US) and London (UK) – June 9, 2021. The Dementia Discovery Fund (DDF) is pleased to announce that Caraway Therapeutics, (…)
Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders
CAMBRIDGE, MA – June 9, 2021 – Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to (…)
Transine Therapeutics Closes Extended Seed Funding of £9.1 million co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to advance its novel class of therapeutic RNAs
New Company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression Cambridge, UK, 2nd June 2021: Transine Therapeutics (…)
Caraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinson’s Disease
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Caraway Therapeutics today announced that the Company has been awarded a second research grant from The Michael J. Fox (…)
Nitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson
Nitrome SAB composed of esteemed experts and key scientific thought leaders in neurobiology and drug development SAN FRANCISCO, Nov. 12, (…)
Excellent news today from our portfolio company @Cerevance on the expansion of its Series B financing round, adding a further $20 million to the $45 million announced in April.
The additional proceeds will aid in the development of the company’s NETSseq platform which it is using to discover entirely (…)
AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer’s Disease
MANCHESTER, England, June 2, 2020 /PRNewswire/ — The therapeutics biotech AstronauTx announces a partnership with Concept Life Sciences, Contract Research (…)
Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases
Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related DiseasesThe (…)
Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer – an industry veteran who brings deep experience in drug development from leadership roles at Regeneron and Vertex
CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new (…)
Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia
London, UK – 15th March 2017 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments (…)